

## **Product** Data Sheet

# Taniborbactam hydrochloride

Cat. No.: HY-109124A

CAS No.: 2244235-49-0

Molecular Formula: C<sub>19</sub>H<sub>30</sub>BCl<sub>2</sub>N<sub>3</sub>O<sub>5</sub>

Molecular Weight: 462.18

Target: Bacterial; Beta-lactamase

Pathway: Anti-infection

**Storage:** -20°C, protect from light, stored under nitrogen

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under

nitrogen)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 200 mg/mL (432.73 mM; Need ultrasonic) H<sub>2</sub>O: 33.33 mg/mL (72.11 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1637 mL	10.8183 mL	21.6366 mL
	5 mM	0.4327 mL	2.1637 mL	4.3273 mL
	10 mM	0.2164 mL	1.0818 mL	2.1637 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 50 mg/mL (108.18 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (10.82 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility:  $\geq$  5 mg/mL (10.82 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (10.82 mM); Clear solution
- 5. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
- 6. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
- 7. Add each solvent one by one: 1% DMSO >> 99% saline Solubility: ≥ 0.5 mg/mL (1.08 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	Taniborbactam hydrochloride (VNRX-5133 hydrochloride) is a reversible and selective boronic acid-containing panspectrum $\beta$ -lactamase inhibitor with IC <sub>50</sub> s of 8-530 nM. Taniborbactam hydrochloride has IC <sub>50</sub> s of 30 nM, 32 nM, 42 nM, 20 nM for KPC-2, AmpC, OXA-48, and VIM-2. Taniborbactam hydrochloride is against Gram-negative bacteria <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	$\beta$ -lactamase $^{[1]}$
In Vitro	Taniborbactam hydrochloride (VNRX-5133 hydrochloride) has $IC_{50}s$ of 0.5 nM, 2 nM, 0.5 nM, 0.06 nM for KPC-2, OXA-48, VIM-4 of K.pneumoniae strain and VIM-2 of P.aeruginosa strain <sup>[2]</sup> . Both cefepime/Taniborbactam hydrochloride (10 $\mu$ g/mL) and meropenem/Taniborbactam hydrochloride combinations are highly active against all six of the NDM-1-producing clinical isolates from K.pneumoniae and E.coli, with MIC ranges of 16-0.25 and 1-0.125 $\mu$ g/mL, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	A single dose of Cefepime (HY-B0692) (32 mg/kg)/Taniborbactam hydrochloride (VNRX-5133 hydrochloride; 16 mg/kg; s.c.) achieves $>4 \log_{10}$ reduction in viable bacterial counts in the neutropenic mouse lung infection model against a CTX-M-14-producing strain of K.pneumoniae <sup>[2]</sup> . Combination of Cefepime (16 mg/kg) and Taniborbactam hydrochloride (16 mg/kg; s.c.; twice-a-day for 7 days) demonstrates $>2 \log_{10}$ reductions in viable bacterial counts in the kidney of the ascending urinary tract infection model against a CTX-M-15-producing strain of E.coli <sup>[2]</sup> . Taniborbactam hydrochloride has a $T_{1/2}$ of 0.16 hours, a CL of 618 mL/h/kg, and a $V_{ss}$ of 143 mL/kg for mice <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- Int J Antimicrob Agents. 2023 Nov 4:107030.
- J Antimicrob Chemother. 2023 Mar 15;dkad061.
- Antimicrob Agents Chemother. 2023 May 31;e0033923.
- Antimicrob Agents Chemother. 2021 Nov 22;AAC0167621.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

#### **REFERENCES**

[1]. Liu B ,et al. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2019 Dec 16.

[2]. Krajnc A, et al. Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases. J Med Chem. 2019 Sep 26;62(18):8544-8556.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA